# ATAC - Quality of Life Sub-Protocol

> **NCT00784680** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 308 (actual)

## Conditions studied

- Quality of Life

## Interventions

- **DRUG:** Anastrozole
- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT00784680
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-04
- **Primary completion:** —
- **Final completion:** 2004-04
- **Target enrollment:** 308 (ACTUAL)
- **Last updated:** 2009-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00784680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00784680, "ATAC - Quality of Life Sub-Protocol". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00784680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*